Antitumor effects of imatinib mesylate and synergistic cytotoxicity with an arsenic compound in neuroblastoma cell lines

Kim,Kyung-Jin; Jung,Jung-Moon; Cho,Jung-Youn; Woo,So-Youn; Cho,Kyung-Ah; Ryu,Kyung-Ha; Yoo,Eun-Sun

doi:10.3892/etm.2011.220

May-June 2011 Volume 2 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-June 2011 Volume 2 Issue 3

Full Size Image

Article

Antitumor effects of imatinib mesylate and synergistic cytotoxicity with an arsenic compound in neuroblastoma cell lines

Authors:
- Kyung-Jin Kim
- Jung-Moon Jung
- Jung-Youn Cho
- So-Youn Woo
- Kyung-Ah Cho
- Kyung-Ha Ryu
- Eun-Sun Yoo
View Affiliations / Copyright

Affiliations: Department of Microbiology, School of Medicine, Ewha Womans University, Seoul, Republic of Korea, Department of Pediatrics, School of Medicine, Ewha Womans University, Seoul, Republic of Korea
Pages: 557-561
|
Published online on: February 28, 2011

https://doi.org/10.3892/etm.2011.220
Expand metrics +

Abstract

Neuroblastoma is a common tumor in childhood and exhibits heterogeneity and malignant progression. MYCN expression and amplification profiles are frequently correlated with the efficacy of therapy. Arsenic trioxide and imatinib mesylate (STI-571) have been suggested as promising therapeutic agents for neuroblastoma, which has been shown to be resistant to conventional therapy. In order to ascertain whether the combination of arsenic trioxide and STI-571 exerts a synergistic cytotoxic effect on neuroblastoma cells in relation to MYCN status, we evaluated cellular proliferation after 72 h of exposure to arsenic trioxide and STI-571 with or without siRNA against MYCN in SH-SY5Y, SK-N-SH and SK-N‑BE(2) neuroblastoma cells. Arsenic trioxide and STI-571 demonstrated a synergistic inhibitory effect on cellular proliferation, while MYCN knockdown had an antagonistic effect on this combined treatment. These results indicate that STI-571 treatment may prove effective for MYCN-expressing or MYCN-amplified neuroblastoma. Furthermore, siRNA therapy targeted to MYCN should be avoided in combination with STI-571 treatment in cases of neuroblastoma.

View Figures

View References

1.	Woo SY, Lee MY, Jung YJ, Yoo ES, Seoh JY, Shin HY, Ahn HS and Ryu KH: Arsenic trioxide inhibits cell growth in SH-SY5Y and SK-N-AS neuroblastoma cell lines by a different mechanism. Pediatr Hematol Oncol. 23:231–243. 2006. View Article : Google Scholar : PubMed/NCBI
2.	Krause DS and van Etten RA: Tyrosine kinases as targets for cancer therapy. N Engl J Med. 353:172–187. 2005. View Article : Google Scholar : PubMed/NCBI
3.	Mauro MJ, O’Dwyer M, Heinrich MC and Druker BJ: STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol. 20:325–334. 2002. View Article : Google Scholar : PubMed/NCBI
4.	Beppu K, Jaboine J, Merchant MS, Mackall CL and Thiele CJ: Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst. 96:46–55. 2004. View Article : Google Scholar : PubMed/NCBI
5.	Kang JH, Rychahou PG, Ishola TA, Qiao J, Evers BM and Chung DH: MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells. Biochem Biophys Res Commun. 351:192–197. 2006. View Article : Google Scholar : PubMed/NCBI
6.	Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL and Tsiatis AA: Cytogenetic features of human neuroblastomas and cell lines. Cancer Res. 41:4678–4686. 1981.PubMed/NCBI
7.	Gilbert F, Feder M, Balaban G, Brangman D, Lurie DK, Podolsky R, Rinaldt V, Vinikoor N and Weisband J: Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res. 44:5444–5449. 1984.PubMed/NCBI
8.	Paffhausen T, Schwab M and Westermann F: Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells. Cancer Lett. 250:17–24. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Gomez-Casares MT, Vaque JP, Lemes A, Molero T, Delgado MD and Leon J: C-myc expression in cell lines derived from chronic myeloid leukemia. Haematologica. 89:241–243. 2004.PubMed/NCBI
10.	Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ and Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 295:139–145. 2000.
11.	Vitali R, Cesi V, Nicotra MR, McDowell HP, Donfrancesco A, Mannarino O, Natali PG, Raschella G and Dominici C: c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571. Int J Cancer. 106:147–152. 2003. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Antitumor effects of imatinib mesylate and synergistic cytotoxicity with an arsenic compound in neuroblastoma cell lines

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles